NCT06041646View on ClinicalTrials.gov

Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 12, 2023

Primary Completion Date

April 29, 2024

Study Completion Date

April 29, 2024

Conditions
Bipolar DisorderSchizophreniaAgitation,PsychomotorSchizo Affective DisorderSchizophreniform Disorders
Interventions
DRUG

Sublingual film containing Igalmi

Sublingual film containing 180 µg of Igalmi (dexmedetomidine)

Trial Locations (2)

72211

BioXcel Clinical Research Site, Little Rock

72758

BioXcel Clinical Research Site, Rogers

Sponsors
All Listed Sponsors
collaborator

Lotus Clinical Research, LLC

OTHER

lead

BioXcel Therapeutics Inc

INDUSTRY